A randomized phase II trial of adjuvant therapy with S-1 plus Hotyu-ekki-to (TJ41) versus S-1 alone for stage II/III gastric cancer
Latest Information Update: 24 Apr 2019
At a glance
- Drugs TJ 41 (Primary) ; Gimeracil/oteracil/tegafur
- Indications Gastric cancer
- Focus Therapeutic Use
Most Recent Events
- 10 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 21 Mar 2011 Actual initiation date (Mar 2011) added as reported by University Hospital Medical Information Network - Japan record.
- 21 Mar 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.